Results 211 to 220 of about 169,027 (313)

Antitumor Activities of a Humanized Cancer-Specific Anti-HER2 Monoclonal Antibody, humH₂Mab-250 in Human Breast Cancer Xenografts. [PDF]

Int J Mol Sci
Kaneko MK, Suzuki H, Ohishi T, Nakamura T, Yanaka M, Tanaka T, Kato Y.   +6 more
europepmc   +1 more source

Induction Camrelizumab and Modified TPF (Nab‐Paclitaxel, Cisplatin, and S‐1) in Locoregionally Advanced Nasopharyngeal Carcinoma

Cancer Science, EarlyView.
ABSTRACT Induction chemo‐immunotherapy has emerged as a potential treatment option for locoregionally advanced nasopharyngeal carcinoma (LANPC). This study aimed to evaluate the efficacy and safety of camrelizumab combined with modified TPF (nab‐paclitaxel, cisplatin, and S‐1) as induction chemo‐immunotherapy in LANPC.
Yi‐Feng Yu, Ya‐Qing Dai, Zong‐Kai Zhang, Guan‐Zhong Lu, Qin Lin, San‐Gang Wu   +5 more
wiley   +1 more source

Potentiating Antibody-Dependent Cellular Cytotoxicity in Triple-Negative Breast Cancer via the Humanized Anti-CD147 Antibody. [PDF]

Antibodies (Basel)
Thongheang K, Pamonsupornwichit T, Sornsuwan K, Juntit OA, Chokepaichitkool T, Thongkum W, Yasamut U, Tayapiwatana C.   +7 more
europepmc   +1 more source

Design of a humanized CD40 agonist antibody with specific properties using AlphaFold2 and development of an anti-PD-L1/CD40 bispecific antibody for cancer immunotherapy. [PDF]

Transl Oncol
Du K, Huang H.
europepmc   +1 more source

Correspondence to ‘Interleukin‐5 as a Pleiotropic Cytokine Orchestrating Airway Type 2 Inflammation: Effects on and Beyond Eosinophils’

Allergy, EarlyView.
Christopher McCrae, Maria L. Jison, Andrew Menzies‐Gow   +2 more
wiley   +1 more source

Safety of an Intravitreal Bevacizumab Biosimilar (MVASI)

Clinical &Experimental Ophthalmology, EarlyView.
ABSTRACT Background Intravitreal bevacizumab has been used off‐label to treat multiple ocular conditions for almost two decades. Reference bevacizumab, Avastin, was discontinued in Australia in 2021. A bevacizumab biosimilar, MVASI, was approved by the Therapeutic Goods Administration for the treatment of metastatic cancer in 2020.
Hanru Wang, Bobak Bahrami, Sonia Huang, Marzieh Tahmasebi Sarvestani, Sudha Cugati, Stewart Lake, Weng Onn Chan, Devaraj Supramaniam, Matthew Little   +8 more
wiley   +1 more source

Repulsive Guidance Molecule-A as a Therapeutic Target Across Neurological Disorders: An Update. [PDF]

Int J Mol Sci
Tseriotis VS, Liampas A, Lazaridou IZ, Karachrysafi S, Vavougios GD, Hadjigeorgiou GM, Papamitsou T, Kouvelas D, Arnaoutoglou M, Pourzitaki C, Mavridis T.   +10 more
europepmc   +1 more source

Targeting the chemokine receptor CXCR4 for cancer therapies. [PDF]

Biomark Res
Rueda A, Serna N, Mangues R, Villaverde A, Unzueta U.   +4 more
europepmc   +1 more source

A novel agent targeting APRIL: A new hope for elderly patients of IgA nephropathy. [PDF]

Aging Med (Milton)
Liu X, Zuo L.
europepmc   +1 more source

Haemophilia Prophylaxis in the Age of Innovation: Exploring Opportunities for Personalized Treatment

Haemophilia, EarlyView.
ABSTRACT Introduction Recent advancements in haemophilia treatment have introduced a range of innovative therapies, including activated FVIII mimetics, ultra‐extended half‐life recombinant FVIII, rebalancing agents and gene therapy. These developments have transformed treatment options and expanded prophylaxis strategies.
Yesim Dargaud, Fabienne Volot, Stephanie Desage, Claire Pouplard, Valerie Chamouard, Anne Lienhart   +5 more
wiley   +1 more source